2022 Fiscal Year Final Research Report
Examination of hearing prognostic factors in Ménière's disease from the perspective of immune and stress responses
| Project/Area Number |
20K09688
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56050:Otorhinolaryngology-related
|
|---|
| Research Institution | Gifu University |
|---|
Principal Investigator |
Aoki Mitsuhiro 岐阜大学, 大学院医学系研究科, 招へい教員 (30283302)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
奥田 弘 岐阜大学, 医学部附属病院, 助教 (20769509)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | メニエール病 / 両側化 / 進行性難聴 / 慢性炎症 |
|---|
| Outline of Final Research Achievements |
MCP-1 exerts its efficacy by binding to its receptor, C-C chemokine receptor type 2 (CCR2). MCP-1 and CCR2 are not expressed in normal vascular walls, but their expression increases in vascular wall cells from the early stage of vascular injury. We reported that plasma MCP-1 in refractory Meniere's disease patients was significantly elevated compared to healthy adults, and that this was significant in bilateral Meniere’s disease patients. In Meniere's disease cases, either NF-κB signaling is enhanced or the downstream monocyte chemoattractant MCP-1 is increased, resulting in increased levels of TNF-α and IL-6, leading to a slow progressive disease. It was thought to cause hearing impairment and vestibular damage.
|
| Free Research Field |
耳科学
|
| Academic Significance and Societal Importance of the Research Achievements |
メニエール病は自然治癒あるいは薬物に反応して速やかに軽快する症例もいる一方、すべての薬物治療に抵抗を示し、強度が高い治療法を選択せざるをない場合もあり、中耳加圧治療や内リンパ嚢開放術が行われている。めまいは制御できたとしても、大半の症例で難聴や平衡障害の進行がみられ、47％のケースで両側化すると言われている。特に、40歳～50歳で発症することが多く、社会活動に多大な影響を及ぼすため、経済的損出は極めて大きい。しかし、進行する難聴や前庭障害ならびに両側化に至るメカニズムは不明である。メニエール病の進行性難聴や両側化を予防あるいは抑制できる治療法の開発につなげることができる。
|
